Reply by Authors

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence

“…While the National Comprehensive Cancer Network guidelines support the option of AS in cases of low or intermediate risk for prostate cancer, the bigger question is whether the riskbenefit profile in these patients necessitates treatment with enzalutamide or another drug. A recent meta-analysis of more than 6700 men showed a 99.8 cancer-specific survival at 6.7 years of follow up, with a 0.4% rate of systemic progression, 4 values that are similar to other AS cohorts. Generally, these men will do well if followed closely.…”